An increase in lesion density can predict lower local recurrence after transarterial chemoembolization in patients with hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 60, Issue 125, 2013, Pages 965-970

  Imai, Norihiro ^a   Katano, Yoshiaki ^a   Kuzuya, Teiji ^a   Honda, Takashi ^a   Hayashi, Kazuhiko ^a   Ishigami, Masatoshi ^a   Itoh, Akihiro ^a   Hirooka, Yoshiki ^a   Goto, Hidemi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Increased lesion density; Local recurrence rate; TACE

Indexed keywords

CISPLATIN; DECARBOXYPROTHROMBIN; EPIRUBICIN; IA CALL; IODINATED POPPYSEED OIL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SIZE; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; PROTHROMBIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84885740864     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge121229     Document Type: Article

References (33)

1. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 11:340(10):745-750.
2. Parkin DM, Bray F, Ferlay J, et al.: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
3. Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19:271-285.
4. Okuda K, Fujimoto I, Hanai A, et al.: Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987; 47:4967-4972.
5. Kudo M: Early detection and curative treatment of early-stage hepatocellular carcinoma. Clin Gastroenterol Hepatol 2005; 3:S144-148.
6. Yamada R, Sato M, Kawabata M, et al.: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148:397-401.
7. Lin DY, Liaw YF, Lee TY, et al.: Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Gastroenterology 1988; 94:453-456.
8. Ikeda K, Kumada H, Saitoh S, et al.: Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. Cancer 1991; 68:2150-2154.
9. Llovet JM, Real MI, Montaña X, et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739.
10. Lo CM, Ngan H, Tso WK et al.: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171.
11. Camma C, Schepis F, Orlando A, et al.: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224:47-54.
12. Ikeda M, Maeda S, Shibata J, et al.: Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 2004; 66:24-31.
13. Takayasu K, Arii S, Ikai I, et al.: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131:461-469.
14. Shim JH, Kim KM, Lee YJ, et al.: Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. Ann Surg Oncol 2010; 17(3):869-877.
15. Miyayama S, Matsui O, Yamashiro M, et al.: Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portel vein with iodized oil. J Vasc Interv Radiol 2007; 18(3):365-376.
16. Hayashi K, Ina H, Tezuka M, et al.: Local therapeutic results of computed tomography-guided transcatheter arterial chemoembolization for hepatocellular carcinoma: results of 265 tumors in 79 patients. Cardiovasc Intervent Radiol 2007; 30(6):1144-1155.
17. Kawamura Y, Ikeda K, Hirakawa M, et al.: Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. Hepatol Res 2009; 39:346-354.
18. Imai N, Ikeda K, Seko Y, et al.: Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Oncology 2011; 80(3-4):188-194.
19. Imai N, Ikeda K, Kawamura Y, et al.: Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Jpn J Clin Oncol 2012; 42(3):175-182.
20. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60.
21. Marelli L, Stigliano R, Triantos C, et al.: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30:6-25.
22. Takayasu K, Moriyama N, Muramatsu Y, et al.: Hepatic arterial embolization for hepatocellular carcinoma. Comparison of CT scans and resected specimens. Radiology 1984; 150(3):661-665.
23. Takayasu K, Arii S, Matsuo N, et al.: Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol 2000; 175(3):699-704.
24. Herber S, Biesterfeld S, Franz U, et al.: Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome. Cardiovasc Intervent Radiol 2008; 31(4):768-777.
25. Choi BI, Kim HC, Han JK, et al.: Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings. Radiology 1992; 182(3):709-713.
26. Riaz A, Lewandowski RJ, Kulik L, et al.: Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol 2010; 33(6):1143-1152.
27. Kwan SW, Fidelman N, Ma E, et al.: Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: A radiological-pathological correlation. Liver Transpl 2012; 18(6):727-736.
28. Miyayama S, Mitsui T, Zen Y, et al.: Histopathological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Res 2009; 39(4):374-381.
29. de Baere T, Zhang X, Aubert B, et al.: Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. Radiology 1996; 201(3):731-735.
30. Matsumura Y, Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46:6387-6392.
31. Kamada K, Nakanishi T, Kitamoto M, et al.: Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 2001; 12:847-854.
32. Ikeda M, Maeda S, Ashihara H, et al.: Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma. J Gastroenterol 2010; 45:60-67.
33. Maeda M, Uchida NA, Sasaki T: Liposoluble platinum (II) complexes with antitumor activity. Jpn J cancer Res 1986; 77:523-525.